Tagrisso combined with chemotherapy improved how long patients with EGFR- and TP53-mutant NSCLC lived without their cancer ...

The findings could fill a treatment gap for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who also carry TP53 mutations.

WU-KONG28 was an open-label, randomized, confirmatory phase 3 study across 16 countries, using blinded independent central ...

The FDA approval of amivantamab-vmjw (Rybrevant) in combination with chemotherapy is the first targeted treatment to cut disease progression risk for EGFR-positive non–small cell lung cancer (NSCLC).

The open-label trial enrolled patients across 16 countries and regions in Europe, Asia, South America, and North America.

Uncommon EGFR mutations, such as exon 20 insertions, account for nearly one-third of EGFR-driven NSCLC, complicating treatment strategies due to their diversity and structural challenges. Traditional ...

First-line aumolertinib plus platinum-pemetrexed chemotherapy significantly improved progression-free survival (PFS) compared with aumolertinib alone in certain patients with epidermal growth factor ...

Osimertinib (Tagrisso) demonstrated promising clinical activity as first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with uncommon EGFR mutations, the nonrandomized ...

Findings showed datopotamab deruxtecan demonstrated a confirmed objective response rate of 45% (95% CI, 35-54). The Food and Drug Administration (FDA) has granted accelerated approval to Datroway ® ...

The prevalence and outcomes of hypercalcemia in Black American patients hospitalized with lung cancer: Findings from the Nationwide Inpatient Sample. This is an ASCO Meeting Abstract from the 2025 ...